lipolysis comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-05-09. Numbers and descriptions here follow the published literature rather than marketing material.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 44-residue peptide | GHRH analog backbone |
| Approximate molecular mass | 5136 Da | Varies with counterion and hydration state |
| N-terminal group | trans-3-hexenoyl | Increases resistance to dipeptidyl peptidase IV |
| Primary receptor | GHRH receptor (GHRHR) | Class B G protein-coupled receptor on somatotrophs |
| Principal mediator | IGF-1 | Rises indirectly after growth hormone release |
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Published work tends to frame tesamorelin as a tool for studying the GHRH axis and as a compound with measurable effects on body composition. Reports often describe visceral adipose tissue as an endpoint, assessed by imaging rather than by inference. Analytical sections commonly describe liquid chromatography with tandem mass spectrometry to confirm identity and purity, because immunoassays may cross-react with related fragments. Where results diverge between studies, differences in assay choice, sampling timing, and population are frequent explanations offered. Whether effects persist after treatment stops remains an open question.
Tesamorelin binds the growth hormone–releasing hormone receptor on pituitary somatotroph cells. The receptor signals through the Gs protein, raising intracellular cAMP and activating protein kinase A. That cascade triggers release of stored growth hormone in pulses rather than a steady stream. Because the drug acts at the receptor that normally controls this process, its effect depends on the body's own signaling architecture rather than on a synthetic pathway. The resulting hormone profile reflects the timing of each pulse, not only its size.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
== Differentiating pre-existing and substance induced == The identification of substance-induced versus independent psychiatric symptoms or disorders has important treatment implications and often constitutes a challenge in daily clinical practice. Similar patterns of comorbidity and risk factors in individuals with substance induced disorder and those with independent non-substance induced psychiatric symptoms suggest that the two conditions may share underlying etiologic factors. Substance use disorders, including those of alcohol and prescription medications, can induce a set of symptoms which resembles mental illness, which can make it difficult to differentiate between substance induced psychiatric syndromes and pre-existing mental health problems. More often than not psychiatric disorders among people who use alcohol or illicit substances disappear with prolonged abstinence. Substance induced psychiatric symptoms can occur both in the intoxicated state and also during the withdrawal state. In some cases, these substance induced psychiatric disorders can persist long after detoxification, such as prolonged psychosis or depression after amphetamine or cocaine use. Use of hallucinogens can trigger delusional and other psychotic phenomena long after cessation of use and cannabis may trigger panic attacks during intoxication and with use it may cause a state similar to dysthymia. Severe anxiety and depression are commonly induced by sustained alcohol use which in most cases abates with prolonged abstinence.
== External links == Boston University School of Medicine: Michael F. Holick Harvard Catalyst Profiles: Michael Holick Search Results for author Holick MF on PubMed. Last capture of VitaminDhealth.org Dr. Holick’s current webpage
Many libraries utilize peptide chains much shorter than 70 amino acids. For 20 encoded amino acids at maximally 70 positions, this results in an upper limit of 2070, or more than 10 quindecillion (1×1091), possible combinations, not accounting for the potential use of amino acids with post-translational modifications or amino acids not encoded in the genetic code, such as selenocysteine and pyrrolysine. Peptide libraries generally encompass only a fraction of this diversity, selected for depending on the needs of the experiment, for instance keeping some amino acids constant at certain positions. Large random peptide libraries are often used for the synthesis of certain peptide molecules, such as ultra-large chemical libraries for the discovery of high-affinity peptide binders. Any increase in the library size severely affects parameters, such as the synthesis scale, the number of library members, the sequence deconvolution and peptide structure elucidation. To mitigate these technical challenges, an algorithm-supported approach to peptide library design may use molecular mass and amino acid diversity to simplify the laborious permutation identification in complex mixtures when using mass spectrometry. This approach is used to avoid mass redundancy. Biological reagent companies, such as Pepscan, ProteoGenix, Mimotopes, GenScript and many others, manufacture customized peptide libraries.
== History == Martin Freund and (Jakob) Edmund Speyer of the University of Frankfurt in Germany published the first synthesis of oxycodone from thebaine in 1916. When Freund died, in 1920, Speyer wrote his obituary for the German Chemical Society. Speyer, born to a Jewish family in Frankfurt am Main in 1878, became a victim of the Holocaust. He died on 5 May 1942, the second day of deportations from the Lodz Ghetto; his death was noted in the ghetto's chronicle. The first clinical use of the drug was documented in 1917, the year after it was first developed. It was first introduced to the U.S. market in May 1939. In early 1928, Merck introduced a combination product containing scopolamine, oxycodone, and ephedrine under the German initials for the ingredients SEE, which was later renamed Scophedal (SCOpolamine, ePHEDrine, and eukodAL) in 1942. It was last manufactured in 1987 but can be compounded. This combination is essentially an oxycodone analogue of the morphine-based "twilight sleep", with ephedrine added to reduce circulatory and respiratory effects. The drug became known as the "Miracle Drug of the 1930s" in Continental Europe and elsewhere and it was the Wehrmacht's choice for a battlefield analgesic for a time. The drug was expressly designed to provide what the patent application and package insert referred to as "very deep analgesia and profound and intense euphoria" as well as tranquillisation and anterograde amnesia useful for surgery and battlefield wounding cases.
== Medical uses == In the European Union, melphalan is indicated for the treatment of multiple myeloma; malignant lymphoma (Hodgkin, non-Hodgkin lymphoma); acute lymphoblastic and myeloblastic leukemia; childhood neuroblastoma; ovarian cancer; and mammary adenocarcinoma. In the United States, melphalan is used as a high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in people with multiple myeloma. In the European Union, it is indicated, in combination with other cytotoxic medicinal products, as reduced intensity conditioning treatment prior to allogeneic haematopoietic stem cell transplantation in malignant haematological diseases in adults. In August 2023, the US Food and Drug Administration approved melphalan (Hepzato) as a liver-directed treatment for adults with uveal melanoma with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease, or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation.
Sources: en.wikipedia.org
Pentose phosphate pathway, which begins with the dehydrogenation of glucose-6-phosphate, the first intermediate to be produced by glycolysis, produces various pentose sugars, and NADPH for the synthesis of fatty acids and cholesterol. Glycogen synthesis also starts with glucose-6-phosphate at the beginning of the glycolytic pathway. Glycerol, for the formation of triglycerides and phospholipids, is produced from the glycolytic intermediate glyceraldehyde-3-phosphate. Various post-glycolytic pathways: Fatty acid synthesis Cholesterol synthesis The citric acid cycle which in turn leads to: Amino acid synthesis Nucleotide synthesis Tetrapyrrole synthesis Although gluconeogenesis and glycolysis share many intermediates the one is not functionally a branch or tributary of the other. There are two regulatory steps in both pathways which, when active in the one pathway, are automatically inactive in the other. The two processes can therefore not be simultaneously active. Indeed, if both sets of reactions were highly active at the same time the net result would be the hydrolysis of four high energy phosphate bonds (two ATP and two GTP) per reaction cycle. NAD+ is the oxidizing agent in glycolysis, as it is in most other energy yielding metabolic reactions (e.g. beta-oxidation of fatty acids, and during the citric acid cycle). The NADH thus produced is primarily used to ultimately transfer electrons to O2 to produce water, or, when O2 is not available, to produce compounds such as lactate or ethanol (see Anoxic regeneration of NAD+ above).
=== Acute === Patulin is toxic primarily through affinity to sulfhydryl groups (SH), which results in inhibition of enzymes. Oral LD50 in rodent models have ranged between 20 and 100 mg/kg. In poultry, the oral LD50 range was reported between 50 and 170 mg/kg. Other routes of exposure are more toxic, yet less likely to occur. Major acute toxicity findings include gastrointestinal problems, neurotoxicity (i.e. convulsions), pulmonary congestion, and edema.
== History == Herodotus notes that cherry juice was consumed by the Argippaeans, either fresh or mixed with milk. Cherry juice was also drunk by ancient Romans. In the late 19th century, cherry juice was not produced in the United States, and was imported from Germany. The imported juice was used by wholesale liquor and drug companies, as well as soda producers. Drug companies typically used the juice to produce syrups for soda water, and liquor companies used it to produce cherry brandy, cherry bounce and liqueurs. German-imported cherry juice was fortified with alcohol to prevent the juice from fermenting, which would spoil it. During this time, juice produced in Magdeburg, Germany from black cherries grown in the area was typically exported to the U.S.
The U.S. Congress extended American citizenship to all Native Americans in 1924; this law has been held to include the indigenous peoples of Alaska. A hospital was built in Unalaska in 1933 by the U.S. Bureau of Indian Affairs.
Sources: en.wikipedia.org
In 1977, eager to return to acting, Kidder read for the character of Lois Lane in Superman: The Movie, only one month before principal photography was scheduled to begin. Kidder was flown to England for screen tests. Upon meeting with director Richard Donner, Kidder tripped while walking into the room. Donner recalled: "I just fell in love with her. It was perfect, this clumsy [behavior]." She was ultimately cast in the role, which would become her most iconic. Filming lasted about 18 months. Superman was released during Christmas 1978 and was a major commercial success, grossing $300 million worldwide. She was deemed "most charming" by Vincent Canby in The New York Times. James Harwood of Variety said that she "plays perfectly off both of his [Reeve's] personalities and her initial double-entendre interview with Superman is wickedly coy, dancing round the obvious question any red-blooded girl might ask herself about such a magnificent prospect." Sonia Saraiya of Vanity Fair praised her ability to balance Lois's ditzy nature with her ambition and no-nonsense attitude, and wrote: "Kidder played a human woman who could believably both attract and deserve a man who is canonically perfect, with the physique of a Greek god and the moral compass of a saint." For the role, Kidder won the Saturn Award for Best Actress. After completing filming for Superman, Kidder starred as Kathy Lutz in the supernatural horror film The Amityville Horror (1979), which further cemented her status as one of Hollywood's leading ladies.
== Disease relevance == Aminoacylase 1 deficiency (A1D) is a rare disease caused by an autosomal recessive mutation in the aminoacylase 1 gene (ACY1) on chromosome 3p21. The lack of functional aminoacylase 1 caused by A1D results in a dysfunctional urea cycle, causing an array of neurological disorders including seizures, muscular hypotonia, mental retardation, and impaired psychomotor development. A1D has also been associated with autism . Patients with A1D often start expressing symptoms shortly after birth but seem to recover fully in the next few years. Aminoacylase 2 deficiency - also known as Canavan's disease - is another rare disease caused by a mutation in the ASPA gene (on chromosome 17) that leads to a deficiency in the enzyme aminoacylase 2. Aminoacylase 2 is known for the fact that it can hydrolyze N-acetylaspartate while aminoacylase 1 cannot.
== In popular culture == 60Co is the material encasing a massive nuclear warhead attached to a missile called the Alpha-Omega Doomsday Bomb in the film Beneath the Planet of the Apes (1970). In an episode of 9-1-1 (TV series), a truck illegally transporting 60Co causes a hazardous emergency for a team of firefighters. In the 1959 film, City of Fear, 60Co is central to the plot in which an escaped convict obtains the material, believing it to be heroin and endangering the city of Los Angeles.
During charging these reactions and transports go in the opposite direction: electrons move from the positive electrode to the negative electrode through the external circuit. To charge the cell the external circuit has to provide electrical energy. This energy is then stored as chemical energy in the cell (with some loss, e. g., due to coulombic efficiency lower than 1). Both electrodes allow lithium ions to move in and out of their structures with a process called insertion (intercalation) or extraction (deintercalation), respectively. As the lithium ions "rock" back and forth between the two electrodes, these batteries are also known as "rocking-chair batteries" or "swing batteries" (a term given by some European industries). The following equations exemplify the chemistry (left to right: discharging, right to left: charging). The negative electrode half-reaction for the graphite is
His resistance to reform caused military efficiency to lag well behind that of Britain's rivals, a problem that became obvious during the Second Boer War. The situation was only remedied in 1904, when the job of Commander-in-Chief was abolished, and replaced with that of the Chief of the General Staff, which was replaced by the job of Chief of the Imperial General Staff in 1908. An Army Council was created with a format similar to that of the Board of Admiralty, directed by the Secretary of State for War, and an Imperial General Staff was established to coordinate Army administration. The creation of the Army Council was recommended by the War Office (Reconstitution) Committee, and formally appointed by Letters Patent dated 8 February 1904, and by Royal Warrant dated 12 February 1904. The management of the War Office was hampered by persistent disputes between the civilian and military parts of the organisation. The government of H.H. Asquith attempted to resolve this during the First World War by appointing Lord Kitchener as Secretary for War. During his tenure, the Imperial General Staff was virtually dismantled. Its role was replaced effectively by the Committee of Imperial Defence, which debated broader military issues. The War Office decreased greatly in importance after the First World War, a fact illustrated by the drastic reductions of its staff numbers during the inter-war period. Its responsibilities and funding were also reduced. In 1936, the government of Stanley Baldwin appointed a Minister for Co-ordination of Defence, who was not part of the War Office.
Sources: en.wikipedia.org
The amino acid sequence matches human growth hormone-releasing hormone, but the amino terminus carries a trans-3-hexenoyl group instead of a free amine. That single structural change chiefly affects enzymatic stability rather than receptor selectivity.
Growth hormone released from the pituitary stimulates IGF-1 production in the liver and other tissues, so circulating IGF-1 generally rises during exposure. The size of the rise varies between individuals and depends on baseline hormonal status and other concurrent factors.
Reported imaging studies focus on visceral adipose tissue, where reductions are more consistently observed across trials. Subcutaneous depots show smaller and less reproducible changes, so the two compartments should not be treated as equivalent.
It acts upstream at the pituitary receptor and depends on functioning somatotroph cells to produce any effect. Growth hormone injections bypass that step and deliver the hormone directly. The pharmacokinetic profiles and the resulting feedback on the body's own secretion therefore differ.